Local administration of mesenchymal stromal cells is safe and modulates the immune compartment in ulcerative proctitis
Authors:
- Laura F. OuboterLOLaura F. Ouboter
- Marieke C. BarnhoornMBMarieke C. Barnhoorn
- Hein W. VerspagetHVHein W. Verspaget
- Leonie PlugLPLeonie Plug
- Emma S. PoolEPEmma S. Pool
- Karoly SzuhaiKaroly Szuhai
- Lukas J.A.C. HawinkelsLukas J.A.C. Hawinkels
- Melissa van PelMPMelissa van Pel
- Jaap Jan ZwagingaJZJaap Jan Zwaginga
- Dave RoelenDRDave Roelen
- Frits KoningFKFrits Koning
- M. Fernanda PascuttiMPM. Fernanda Pascutti
Open Access
- 8 May 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (9)
Abstract
BACKGROUND: Due to their immunoregulatory and tissue regenerative features, mesenchymal stromal cells (MSCs) are a promising novel tool for the management of ulcerative proctitis (UP). Here we report on a phase IIa clinical study that evaluated the impact of local MSC therapy on UP. METHODS: Thirteen refractory UP patients, with an endoscopic Mayo score (EMS) of 2 or 3, were included. Seven patients received 20–40 million allogeneic MSCs (cohort 1), while 6 patients received 40–80 million MSCs (cohort 2). Adverse events (AEs) were assessed at baseline and on weeks 2, 6, 12, and 24. Clinical, endoscopic, and biochemical parameters were assessed at baseline and on weeks 2 and 6. Furthermore, we evaluated the engraftment of MSCs, the presence of donor-specific human leukocyte antigen (HLA) antibodies (DSAs), and we determined the impact of MSC therapy on the local immune compartment. RESULTS: No serious AEs were observed. The clinical Mayo score was significantly improved on weeks 2 and 6, and the EMS was significantly improved on week 6, compared with baseline. On week 6, donor MSCs were still detectable in rectal biopsies from 4 of 9 patients and DSAs against both HLA class I and class II were found. Mass cytometry showed a reduction in activated CD8 + T cells and CD16 + monocytes and an enrichment in mononuclear phagocytes and natural killer cells in biopsies after local MSC therapy. CONCLUSION: Local administration of allogeneic MSCs is safe, tolerable, and feasible for treatment of refractory UP and shows encouraging signs of clinical efficacy and modulation of local immune responses. This sets the stage for larger clinical trials. TRIAL REGISTRATION: EU Clinical Trials Register (EudraCT, 2017-003524-75) and the Dutch Trial Register (NTR7205). FUNDING: ECCO grant 2020.Keywords
Funding Information
- ECCO grant 2020 (ECCO grant 2020)
This publication has 57 references indexed in Scilit:
- Expanded Adipose-Derived Stem Cells for the Treatment of Complex Perianal FistulaDiseases of the Colon & Rectum, 2009
- Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 productionNature Medicine, 2008
- Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interactionNature, 2006
- A Phase I Clinical Trial of the Treatment of Crohn's Fistula by Adipose Mesenchymal Stem Cell TransplantationDiseases of the Colon & Rectum, 2005
- Ulcerative ProctitisClinics in Colon and Rectal Surgery, 2004
- HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cellsExperimental Hematology, 2003
- Systemic Delivery of Bone Marrow–Derived Mesenchymal Stem Cells to the Infarcted MyocardiumCirculation, 2003
- Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantationTransplantation, 2003
- Progression of ulcerative proctosigmoiditisEuropean Journal of Gastroenterology & Hepatology, 1996
- Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysisAlimentary Pharmacology & Therapeutics, 1995